Missing Institutional Review Board Statement
In the original publication [1], the Institutional Review Board Statement (IRBS) was not included in the Back Matter section in the standard format required by the journal. All experiments in the study were conducted in full compliance with the relevant ethical standards, and the corresponding ethics approvals were obtained prior to the study. The corrected statement is provided below.
The statement has now been added as follows:
- Institutional Review Board Statement: The animal study protocol was approved by the Institutional Review Board (or Ethics Committee) of Fundação Oswaldo Cruz (protocol code P-6/20.3 (LW-17/20) on 6 July 2020 and renewed by protocol code 06/2024-3 (LBM-7/24) on 8 October 2024) by Bio-Manguinhos/Fundação Oswaldo Cruz. The protocol for the use of human samples was approved by the Institutional Review Board of Fundação Oswaldo Cruz (protocol code 34728920.4.0000.5262) on 3 November 2020.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Galuzo, R.; Lazari Machado, T.; de Souza Nascimento, R.; Ramos de Medeiros, J.; Neves Tubarão, L.; Silva, J.; Pimenta Rocha, V.; Azamor, T.; Soares Coelho, F.; da Silva, A.M.V.; et al. CLEC5A Activation in Inflammatory Monocytes: A Mechanism for Enhanced Adaptive Immunity Following COVID-19 mRNA Vaccination in a Preclinical Study. Viruses 2025, 17, 1233. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).